Dermal Priming in Enhancing Vaccine Immunogenicity

Inclusion Criteria:

• Diagnosed with an autoimmune condition (including but not limited to ANCA associated vasculitis, IgG4 disease) and receiving B cell depletion therapy (eg, rituximab).
• Participant is willing and able to give informed consent for participation in the study.

Exclusion Criteria:

• Has received immunosuppression in addition to rituximab in the last 3 months (oral prednisolone at any dose is permitted)
• Rituximab within less than 5 months or more than 18 months of screening
• Receiving oral prednisolone at a dose > 5mg daily
• Has a diagnosis of systemic lupus erythematosus or Sjogren's syndrome
• Is currently pregnant
• Has a recent history (documented, confirmed or suspected) of a flu-like illness within a week of vaccination
• Receiving anticoagulation (including warfarin, DOACs, clopidogrel, ticagrelor) for any indication or having any coagulation disorder. Low dose daily aspirin is permitted
• A known allergy or contraindications to imiquimod or influenza vaccine or excipients
• Prior vaccination with the current seasonal influenza vaccine
• Have any condition that the investigator believes may interfere with successful completion of the study